<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569022</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-005-11F</org_study_id>
    <nct_id>NCT01569022</nct_id>
  </id_info>
  <brief_title>A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder</brief_title>
  <official_title>A Randomized Cross Over Trial of Two Treatments for OSA in Veterans With PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep disturbances are cardinal features of Veterans with post traumatic stress disorder
      (PTSD). In particular, obstructive sleep apnea is reported to occur more frequently in
      patients with PTSD compared to those without PTSD and contribute to worsening cognitive and
      behavioral functions. Continuous positive airway pressure (CPAP) is considered the treatment
      of choice for OSA but adherence to CPAP in Veterans with PTSD is poor compared to the general
      population. The proposed study aims at comparing the efficacy, tolerability, and adherence of
      oral appliances-an alternative therapy to OSA- to CPAP. The study is instrumental in
      identifying the optimal OSA therapy for Veterans with PTSD and the OSA phenotype that would
      predict oral appliance response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) is a prevalent disorder associated with poor neurocognitive
      performance and organ system dysfunction due to intermittent hypoxia and repeated arousals.
      The repetitive hemodynamic stresses are implicated in the increased incidence of systemic
      hypertension and cardiovascular diseases. Insufficient and disrupted sleep has similar
      negative impact on mood, attention, cognition, and behavior. In Veterans with post traumatic
      stress disorder (PTSD), the disturbed sleep can worsen further the cognitive-behavioral
      manifestations of PTSD and contributes to poor mental and physical health outcomes. Recent
      epidemiologic studies largely support the association of higher rates of OSA in patients with
      PTSD compared with the general population. Treatment of the underlying obstructive sleep
      disturbances with continuous positive airway pressure (CPAP) has resulted in restoration of
      sleep architecture, decrease daytime sleepiness, and reduction in nightmares frequency and
      intensity. However, adherence to treatment with CPAP is less than optimal in Veterans with
      PTSD. Mandibular advancing devices (MADs) are considered non surgical alternatives to CPAP
      and are preferred in a head to head comparison to CPAP in OSA subjects without PTSD. However,
      there has been no study to the investigators' knowledge that has assessed MAD in terms of
      clinical efficacy, compliance, and quality of sleep compared to CPAP in OSA patients with
      PTSD. Therefore, the investigators hypothesize that MAD is not inferior to CPAP in treating
      OSA effectively in Veterans with PTSD and OSA. To that end, the investigators propose to
      conduct a feasibility study using a randomized crossover trial of 12 weeks of CPAP and MAD in
      42 consecutive outpatients with PTSD newly diagnosed with OSA separated by 2 weeks washout
      period.

      The primary endpoint of the trial is to compare the treatment efficacy of CPAP and MAD in
      Veterans with PTSD and OSA. Secondary endpoints aim at: 1) comparing change in the Epworth
      Sleepiness Scale, SF-36, and the Pittsburgh Sleep Quality Index at end of treatment following
      use of CPAP versus MAD, 2) comparing adherence and short-term side effects between using CPAP
      and MAD in PTSD patients with OSA, and 3) determining anthropomorphic, polysomnographic, and
      cephalometric predictors of successful MDA response. Assessments at the end of both limbs
      comprise evaluation of quality of sleep, daytime sleepiness, quality of life, and side
      effects of treatment. Compliance with each therapy will be measured at the end of each
      treatment period.

      The results of the trial are pivotal in determining the efficacy, tolerability, and adherence
      to MAD compared to CPAP in Veterans with PTSD and OSA. This feasibility study would form the
      basis of a future trial examining the effectiveness of various therapeutic modalities for OSA
      on PTSD symptomatology and progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2012</start_date>
  <completion_date type="Actual">March 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual Apnea Hypopnea Index</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The primary endpoint of the study was tested by comparing the upper limit of the 95% confidence interval for the CPAP-MAD difference in residual AHI with the a priori noninferiority margin using the paired t test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Health outcomes including ESS, PCL-M, and PSQI. ESS is a short questionnaire validated to measure excessive daytime sleepiness in patients with OSA 17. It measures the likelihood of falling asleep in eight different situations, with a score of 0-3 for each situation. The sum of individual scores for the eight items gives the final ESS score, ranging from 0-21. An ESS score &gt;10 suggests excessive daytime sleepiness (EDS). The PSQI is a self-rating questionnaire that consists of seven dimensions. The possible scores range from 0-21, with greater than five indicative of impaired sleep quality. The PTSD Checklist is a 17-item self-report measure (1-5 points each) that assesses PTSD symptoms in relation to stressful military experiences. PTSD symptom severity scores are determined by summing the participants' answers to all 17 items from 1 (&quot;not at all&quot;) to 5 (&quot;extremely&quot;)(range 17-85) 14 with 5-10 point change indicating statistically significant response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Health SF-36</measure>
    <time_frame>12 weeks</time_frame>
    <description>The SF-36 is a generic 36-item Short Form Medical Outcomes Survey (SF-36) 16. It has eight main domains: physical functioning, role limitation due to physical problems, role limitation due to emotional problems, social functioning, mental health, energy/vitality, bodily pain, and general health perception. General Health SF36 score is coded, summed, and transformed onto a scale from 0 to 100 (worst to best possible health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>comparison of the number of hours per night used while on CPAP versus MAD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP First, MAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CPAP treatment for sleep apnea
CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD First, CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD treatment for sleep apnea
MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP Treatment for 12 weeks</description>
    <arm_group_label>CPAP First, MAD</arm_group_label>
    <arm_group_label>MAD First, CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MAD</intervention_name>
    <description>MAD Treatment for 12 weeks</description>
    <arm_group_label>CPAP First, MAD</arm_group_label>
    <arm_group_label>MAD First, CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients aged 18-70 years of age

          -  Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hr)

          -  Established diagnosis of PTSD related to any past lifetime traumatic event and have a
             diagnosis of current, chronic PTSD

        Exclusion Criteria:

          -  Central sleep apnea defined as central apnea/hypopnea &gt;50% of the total respiratory
             events

          -  Prior treatment for sleep apnea

          -  Veterans with fewer than 4 teeth remaining in either arch

          -  Coexisting narcolepsy

          -  Tempo-mandibular joint disease

          -  Epilepsy

          -  Prominent suicidal or homicidal ideation

          -  Diagnosis of dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali A El-Solh, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Western New York Healthcare System, Buffalo, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Western New York Healthcare System, Buffalo, NY</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>August 25, 2017</results_first_submitted>
  <results_first_submitted_qc>November 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post traumatic stress disorder</keyword>
  <keyword>continuous positive airway pressure</keyword>
  <keyword>oral appliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 127 Veterans were considered for study participation between August 2013 and April 2016. Fifty-four patients agreed to enroll in the study but twelve patients either failed to return for scheduled visits or withdrew from further participation because of lack of time or other pressing matters. Forty-two were randomized to CPAP or MAD.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CPAP First, MAD</title>
          <description>CPAP treatment for sleep apnea
CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>MAD First, CPAP</title>
          <description>MAD treatment for sleep apnea
MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants were asked to acclimate to CPAP and MAD for 4 weeks (total) during which adjustments to both modes of therapy are made aiming to optimize comfort and abolish snoring.
If the interface was found to be uncomfortable, the patient was given the opportunity to change the mask. None of the participants was exposed to dual therapy or had access to both devices at the same time. Weekly phone calls were made to inquire about side effects or problems with CPAP or MAD. At the end of the acclimatization period, patients underwent a 2-week washout, after which they were randomly assigned in 1:1 ratio via a presealed and numbered opaque white envelope to one of the two treatment modalities (CPAP or MAD) that included the assignment to receive 12 weeks of treatment with MAD and CPAP in alternating order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Residual Apnea Hypopnea Index</title>
        <description>The primary endpoint of the study was tested by comparing the upper limit of the 95% confidence interval for the CPAP-MAD difference in residual AHI with the a priori noninferiority margin using the paired t test</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>CPAP treatment for sleep apnea
CPAP: CPAP Treatment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mandibular Advancing Device</title>
            <description>MAD treatment for sleep apnea
MAD: MAD Treatment for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Apnea Hypopnea Index</title>
          <description>The primary endpoint of the study was tested by comparing the upper limit of the 95% confidence interval for the CPAP-MAD difference in residual AHI with the a priori noninferiority margin using the paired t test</description>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.8"/>
                    <measurement group_id="O2" value="26.3" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint of the study was tested by comparing difference in residual AHI using the paired t test</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Outcomes</title>
        <description>Health outcomes including ESS, PCL-M, and PSQI. ESS is a short questionnaire validated to measure excessive daytime sleepiness in patients with OSA 17. It measures the likelihood of falling asleep in eight different situations, with a score of 0-3 for each situation. The sum of individual scores for the eight items gives the final ESS score, ranging from 0-21. An ESS score &gt;10 suggests excessive daytime sleepiness (EDS). The PSQI is a self-rating questionnaire that consists of seven dimensions. The possible scores range from 0–21, with greater than five indicative of impaired sleep quality. The PTSD Checklist is a 17-item self-report measure (1-5 points each) that assesses PTSD symptoms in relation to stressful military experiences. PTSD symptom severity scores are determined by summing the participants’ answers to all 17 items from 1 (“not at all”) to 5 (“extremely”)(range 17-85) 14 with 5-10 point change indicating statistically significant response to treatment</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>CPAP treatment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mandibular Advancing Device</title>
            <description>Mandibular advancing device treatment for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Outcomes</title>
          <description>Health outcomes including ESS, PCL-M, and PSQI. ESS is a short questionnaire validated to measure excessive daytime sleepiness in patients with OSA 17. It measures the likelihood of falling asleep in eight different situations, with a score of 0-3 for each situation. The sum of individual scores for the eight items gives the final ESS score, ranging from 0-21. An ESS score &gt;10 suggests excessive daytime sleepiness (EDS). The PSQI is a self-rating questionnaire that consists of seven dimensions. The possible scores range from 0–21, with greater than five indicative of impaired sleep quality. The PTSD Checklist is a 17-item self-report measure (1-5 points each) that assesses PTSD symptoms in relation to stressful military experiences. PTSD symptom severity scores are determined by summing the participants’ answers to all 17 items from 1 (“not at all”) to 5 (“extremely”)(range 17-85) 14 with 5-10 point change indicating statistically significant response to treatment</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epworth Sleepiness Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="4.7"/>
                    <measurement group_id="O2" value="9.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTSD Checklist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="15.4"/>
                    <measurement group_id="O2" value="50.03" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pitt sleep quality index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="0.2"/>
                    <measurement group_id="O2" value="17.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ESS</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>t test assuming unequal variance</non_inferiority_desc>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PCL</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>t test assuming unequal variance</non_inferiority_desc>
            <p_value>0.98</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PSQI</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>t-test assuming non unequal variance</non_inferiority_desc>
            <p_value>0.31</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Health SF-36</title>
        <description>The SF-36 is a generic 36-item Short Form Medical Outcomes Survey (SF-36) 16. It has eight main domains: physical functioning, role limitation due to physical problems, role limitation due to emotional problems, social functioning, mental health, energy/vitality, bodily pain, and general health perception. General Health SF36 score is coded, summed, and transformed onto a scale from 0 to 100 (worst to best possible health).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>CPAP treatment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mandibular Advancing Device</title>
            <description>Mandibular advancing device treatment for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>General Health SF-36</title>
          <description>The SF-36 is a generic 36-item Short Form Medical Outcomes Survey (SF-36) 16. It has eight main domains: physical functioning, role limitation due to physical problems, role limitation due to emotional problems, social functioning, mental health, energy/vitality, bodily pain, and general health perception. General Health SF36 score is coded, summed, and transformed onto a scale from 0 to 100 (worst to best possible health).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.33" spread="17.09"/>
                    <measurement group_id="O2" value="50.58" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>t test assuming unequal variance</non_inferiority_desc>
            <p_value>0.54</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Therapy</title>
        <description>comparison of the number of hours per night used while on CPAP versus MAD</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>CPAP treatment for sleep apnea
CPAP: CPAP Treatment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mandibular Advancing Device</title>
            <description>MAD treatment for sleep apnea
MAD: MAD Treatment for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Therapy</title>
          <description>comparison of the number of hours per night used while on CPAP versus MAD</description>
          <units>hours per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.48"/>
                    <measurement group_id="O2" value="5.66" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>t test assuming unequal variance</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CPAP</title>
          <description>CPAP treatment for sleep apnea
CPAP: CPAP Treatment for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Mandibular Advancing Device</title>
          <description>MAD treatment for sleep apnea
MAD: MAD Treatment for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>mask discomfort</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>claustrophobia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ali El Solh</name_or_title>
      <organization>VA Western New York</organization>
      <phone>716-862-6525</phone>
      <email>ali.el-solh@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

